Chronic lymphocytic leukaemia (CLL) patients who are refractory or resistant to treatment can be encouraged by data showing significantly longer survival without disease progression with a treatment combining venetoclax and rituximab compared to treatment with bendamustine plus rituximab.
An AI-powered, virtual platform is being developed to improve care for patients living with genetic disorders, as part of a Digital Health CRC project led by Peter MacCallum Cancer Centre and Swinburne University of Technology.
Evusheld is an extra COVID-19 medication that provides added protection for vulnerable patients. Peter Mac is recommending this medication for patients with blood cancer, or cancer patients who are immunosuppressed.
Brian Le has been appointed to the position of Honorary Clinical Professor in both the Sir Peter MacCallum Department of Oncology and the Department of Medicine – Royal Melbourne Hospital at the University of Melbourne.
The Peter MacCallum Cancer Centre acknowledges the traditional
owners of the land on which our five sites are located throughout Victoria.
We recognise their strength and resilience and pay our respects
to their Elders past and present.